Tissue Kallikrein Protect Against Ischemic Stroke
Launched by QIN ZHANG · May 18, 2024
Trial Information
Current as of February 08, 2025
Completed
Keywords
ClinConnect Summary
Analyze the data of a 5-year follow-up on 2115 control individuals from the case-control study of the previous research. We completed the 5-year follow-up on this group in 2016 (whether they had a stroke, whether they are alive, and the cause of death).
Conduct a 12-year follow-up on 6487 community individuals from the previous study (whether they had a stroke within 12 years, whether they are alive, and the cause of death). We collaborated with the hospital platform's computer center to conduct follow-up through AI questionnaire surveys, followed by supplementing AI questionnaire data wit...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1) Control population in the previous stroke case-control study;
- • 2) The CHD case-control population in the previous study;
- • 3) The population in the community cross-sectional study of the previous study.
- Exclusion Criteria:
- • Stroke patient
Trial Officials
QIN Zhang, phd
Principal Investigator
Tongji Hospital
About Qin Zhang
Qin Zhang is a dedicated clinical trial sponsor with a commitment to advancing medical research and innovation. With a focus on developing novel therapeutic solutions, the organization collaborates with leading researchers and healthcare institutions to conduct rigorous clinical trials. Qin Zhang emphasizes ethical standards, patient safety, and data integrity, ensuring that all studies adhere to regulatory requirements and best practices. By fostering a collaborative environment, Qin Zhang aims to contribute significantly to the understanding and treatment of various medical conditions, ultimately improving patient outcomes and quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wuhan, Hubei, China
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0